Statin Equivalency to Rosuvastatin 10 mg
Atorvastatin 20 mg is equivalent to rosuvastatin 10 mg based on moderate-intensity statin classification and LDL-C lowering efficacy.
Direct Equivalency Based on Guidelines
According to the 2018 AHA/ACC Blood Cholesterol Guidelines, rosuvastatin 10 mg and atorvastatin 20 mg are both classified as moderate-intensity statins that lower LDL-C by 30-49% 1, 2. This classification places them in the same therapeutic category for clinical decision-making.
Comparative LDL-C Reduction Data
The FDA-approved labeling and clinical trial data demonstrate:
- Rosuvastatin 10 mg: Reduces LDL-C by approximately 52% 3
- Atorvastatin 20 mg: Reduces LDL-C by approximately 43% 3
While rosuvastatin 10 mg produces slightly greater LDL-C reduction, the VOYAGER meta-analysis (38,052 patient exposures) found that rosuvastatin 10 mg reduced LDL-C by 44%, requiring atorvastatin 29 mg for equivalent reduction 4. However, since atorvastatin 29 mg is not a standard dose, atorvastatin 20 mg remains the clinically appropriate equivalent based on guideline intensity classification.
Alternative Statin Equivalents
Other moderate-intensity options equivalent to rosuvastatin 10 mg include 1, 2:
- Simvastatin 20-40 mg (30-39% LDL-C reduction)
- Pravastatin 40-80 mg (24-30% LDL-C reduction)
- Lovastatin 40-80 mg
- Pitavastatin 1-4 mg
Important caveat: Simvastatin 80 mg should NOT be initiated or titrated to due to FDA warnings about increased myopathy and rhabdomyolysis risk 1, 2.
Potency Comparison
Research confirms rosuvastatin is approximately 3-3.5 times more potent than atorvastatin and 7-8 times more potent than simvastatin on a milligram-per-milligram basis 4. This means:
- Rosuvastatin 5 mg ≈ Atorvastatin 15 mg ≈ Simvastatin 39 mg
- Rosuvastatin 10 mg ≈ Atorvastatin 29 mg ≈ Simvastatin 72 mg
- Rosuvastatin 20 mg ≈ Atorvastatin 70 mg (simvastatin 80 mg insufficient)
Clinical Outcomes Data
The PULSAR trial directly compared rosuvastatin 10 mg versus atorvastatin 20 mg in high-risk patients, showing rosuvastatin 10 mg achieved slightly better LDL-C goal attainment (68.8% vs 62.5%, p<0.05) and HDL-C increases (6.4% vs 3.1%, p<0.001), with similar safety profiles 5. A 2024 real-world cohort study found small differences in mortality favoring rosuvastatin, though differences were modest 6.
Practical Recommendation
For therapeutic interchange or dose conversion: use atorvastatin 20 mg as the equivalent to rosuvastatin 10 mg. Both are moderate-intensity statins with proven cardiovascular benefit in randomized trials, similar safety profiles, and are the most commonly prescribed statins in clinical practice 1, 2, 5.
If switching from rosuvastatin 10 mg to another statin due to cost, tolerance, or availability issues, atorvastatin 20 mg provides the most straightforward 1:1 therapeutic substitution within the same intensity category.